Zydus Lifesciences Ltd. News and Updates

Name: Latest research reports of Zydus Lifesciences Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Zydus Lifesciences Ltd.
Rating: 5
Author: Geojit BNP Paribas

Keep track of all breaking news on Zydus Lifesciences Ltd. from all sources in a single place.

Zydus Lifesciences Ltd.

16 Apr 2025

831.55

1.15%

ZYDUS LIFESCIENCES LIMITED

Buy: Zydus Lifesciences Ltd.

Recommendation Target

Geojit BNP Paribas

Zydus Lifesciences Ltd. is trading below all available SMAs

Zydus Lifesciences Ltd.

07 Feb 2025

831.55

1.15%

New product launches is set to drive growth in US

Buy: Zydus Lifesciences Ltd.

KRChoksey

Zydus Lifesciences’ revenue was largely in-line with our estimates. EBITDA missed our estimates due to lower-than-expected gross profit and higher-than-expected other expenses. However, Adj. PAT was in-line with our estimates as EBITDA miss was offset by lower-than-expected tax expenses.

Zydus Lifesciences L.. has an average target of 1052.33 from 6 brokers.

Zydus Lifesciences Ltd.

06 Feb 2025

831.55

1.15%

ZYDUS LIFESCIENCES L

Accumulate: Zydus Lifesciences Ltd.

Target

Prabhudas Lilladhar

Zydus Lifesciences Ltd. is trading below all available SMAs

Zydus Lifesciences Ltd.

06 Feb 2025

831.55

1.15%

Near-term challenges persist in US

Hold: Zydus Lifesciences Ltd.

Target

ICICI Securities Limited

Zydus Lifesciences’ (Zydus) Q3FY25 revenue was in line with our expectations, but lower sales of gRevlimid and gAsacol led to a miss in earnings.

Zydus Lifesciences Ltd. is trading below all available SMAs

Zydus Lifesciences Ltd.

05 Feb 2025

831.55

1.15%

to see Rapid results content

Zydus Lifesciences Ltd.

18 Nov 2024, 12:00AM

831.55

1.15%

Sustained Growth Across All Segments

Buy: Zydus Lifesciences Ltd.

Target

Sharekhan

Revenue amounted to Rs. 5,237 crore, reflecting a 20% y-o-y increase but a 16% q-o-q decline,
primarily driven by reduced performance in the Indian consumer wellness segment, US
formulations and API business.

Geojit BNP Paribas upgraded Zydus Lifesciences Ltd. to Buy with a price target of 975.0 on 16 Apr, 2025.

Zydus Lifesciences Ltd.

13 Nov 2024

831.55

1.15%

Ongoing litigation and regulatory hurdles weigh on valuation

Buy: Zydus Lifesciences Ltd.

Target

KRChoksey

Zydus Lifesceinces’ revenue was largely in-line with our estimate (-2.7%) due to strong growth across geographical segments. However, Adj. PAT missed our estimate due to higher-than-expected depreciation and tax expenses, and lower-than-expected other income.

Zydus Lifesciences L.. has an average target of 1052.33 from 6 brokers.

Zydus Lifesciences Ltd.

12 Nov 2024

831.55

1.15%

to see Rapid results content

Zydus Lifesciences Ltd.

12 Nov 2024

831.55

1.15%

The US and international markets drive earnings

Neutral: Zydus Lifesciences Ltd.

Target

Motilal Oswal

Zydus LifeSciences (ZYDUSLIF) delivered better-than-expected operational
performance for the quarter. While its revenue grew at a lower rate of 19% YoY (vs. est. of 25%).

Zydus Lifesciences Ltd. is trading below all available SMAs

Zydus Lifesciences Ltd.

03 Oct 2024

831.55

1.15%

R&D advancements to drive growth

Buy: Zydus Lifesciences Ltd.

Target

Sharekhan

Zydus Lifesciences Ltd has partnered with the Central Drug Research Institute (CDRI) to develop an oral
treatment for osteoporosis related to chronic kidney disease (CKD) and postmenopausal conditions, focusing on small-molecule inhibitors of the protein sclerostin.

Zydus Lifesciences L.. has an average target of 1052.33 from 6 brokers.

Is Cadila Healthcare Ltd. worth buying?

835 Votes:

Buy 82.16%

Sell 9.94%

Hold 7.9%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf